An important controversy in urologic surgery is immediate treatment versus active surveillance for small, low-risk kidney tumors. Two respected physicians share their thoughts on the different treatment options.

Continue Reading

Mitchell Benson, MD, Chairman of the Department of Urology at Columbia University and practicing physician at New York-Presbyterian, gives us his perspective on the benefits of immediate treatment for low-risk renal tumors.

David Chen, MD, FACS, of the Department of Surgical Oncology at Fox Chase Cancer Center shares his thoughts on why certain patients should opt for active surveillance when diagnosed.